SOURCE: Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

February 10, 2011 08:03 ET

Agile Therapeutics Announces Upcoming Presentations

Agile to Participate in Business Roundtable at the BIO CEO & Investor Conference

Company to Present Clinical Data at American College of Obstetricians and Gynecologists Annual Clinical Meeting

PRINCETON, NJ--(Marketwire - February 10, 2011) - Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced today that Al Altomari, President and CEO of Agile, will participate in a Business Roundtable entitled, "Business Development - License to Thrill: Building Corporate Value through Partnerships," at the 13th annual BIO CEO & Investor Conference 2011 at the Waldorf-Astoria Hotel in New York. The panel will explore the links between corporate partnerships, regulatory events and value and will take place on Tuesday, February 15, 2011, at 10:30 a.m. Eastern Time. 

Additionally, Agile Therapeutics will present clinical data on the Company's Phase III contraceptive patch, AG200-15, at the upcoming American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting taking place in Washington, D.C., from April 30 - May 4, 2011.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch currently in Phase III clinical trials. In addition, Agile is also developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate proprietary transdermal delivery technology, Skinfusion™, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit

Contact Information

  • Contact:
    Laura Yoshida for Agile Therapeutics
    Email Contact